Wound-Healing Genes in Flies Bode Well for Humans
News Apr 26, 2013
Their discovery, detailed this week in the open-access journal PLoS ONE, was made in the laboratory fruit fly Drosophila. But the biologists say many of the same genes that regulate biological processes in the hard exoskeleton, or cuticle, of Drosophila also control processes in human skin. That makes them attractive candidates for new kinds of wound-healing drugs or other compounds that could be used to treat skin ailments.
“Many of the key molecules and proteins involved in Drosophila wound healing are involved in mammalian wound healing,” says Rachel Patterson, the first author who published the paper with Michelle Juarez and William McGinnis, a professor of biology and interim dean of the Division of Biological Sciences. “The genetics of Drosophila are not as complicated as mammalian genetics, so it’s easier to attribute specific biological functions to individual genes.”
By puncturing the cuticle and epidermis of fruit fly embryos in their experiments, the researchers examined 84 genes that are turned on and 78 that are turned off as the fly embryo responds to healing. From these 162 genes, they identified eight genes that are expressed at either very low levels or not at all in most cells during development, but are activated near the puncture wounds.
The researchers were surprised to discover that an immune response begins as soon as the flies’ cuticles and epidermis were punctured, releasing antimicrobial peptides and other compounds that prepare the embryo should bacteria or fungi enter the site of injury. The key to their technique was the use of trypsin, a member of a family of enzymes called serine proteases, which activates genes involved in wound healing. The next step is to see if these genes play a comparable role in humans.
“I think one amazing application of our studies may be to build a better bandage — containing compounds to promote would healing,” said Juarez, a former postdoctoral fellow in McGinnis’s lab who is now an assistant medical professor at the City College of New York.
“Perhaps our results can be translated to existing human therapies by incorporating specific, regulated series proteases and antimicrobial peptides at the sites of diabetic ulcers or skin grafts for more efficient wound healing,” said Patterson. She said her team’s results might also have application to treating chronic skin diseases such as psoriasis, severe dry skin and eczema in which levels of these enzymes are known to be abnormal. The PLoS ONE paper can be accessed online after the embargo.
Funding for the study was provided by the National Institutes of Health (GM077197 and HD28315), a Developmental Biology of Neural Diseases Training grant, the Ray Thomas Edwards Fellowship and the family of Herbert Stern.
Genetic Discovery Helps Determine the Difference Between Aggressive & Benign Bone TumorsNews
The first genetic marker for the bone tumor, osteoblastoma, has been discovered. Whole-genome and transcriptome sequencing of human bone tumors revealed that a genetic change that affects the transcription factor, FOS, is a hallmark mutation of osteoblastoma. The results will help clinicians correctly distinguish benign osteoblastoma tumors from aggressive osteosarcoma tumors and direct the correct treatment.READ MORE
Improved Method for Isolating Extracellular RNANews
In a breakthrough that could lead to powerful new ways to diagnose and track a wide range of medical conditions, scientists at The Rockefeller University have devised an improved method for isolating and identifying tiny fragments of RNA in human blood products.READ MORE
Comments | 0 ADD COMMENT
27th International Conference on Nanomedicine and Nanomaterials
Oct 18 - Oct 19, 2018